More articles from Critical-Care

  • What is the role for terlipressin in hepatorenal syndrome?
    Stephanie N. Bass, PharmD, Aanchal Kapoor, MD and Christina C. Lindenmeyer, MD
    Cleveland Clinic Journal of Medicine November 2023, 90 (11) 664-667; DOI: https://doi.org/10.3949/ccjm.90a.23037

    The drug is recommended as a first-line treatment of hepatorenal syndrome-related acute kidney injury, but it is associated with respiratory failure, especially in the setting of albumin administration, and certain comorbidities may increase the risk.

  • COVID-19: A management update
    Kathryn Bash, MHSc, MSN, APRN-CNP, Gretchen Sacha, PharmD, BCCCP and Mani Latifi, MD
    Cleveland Clinic Journal of Medicine November 2023, 90 (11) 677-683; DOI: https://doi.org/10.3949/ccjm.90a.22102

    The authors examine current guidelines of the Infectious Diseases Society of America and the National Institutes of Health.

  • Should midodrine be used as an intravenous vasopressor-sparing agent in septic shock?
    Simran Gupta, MD, Ayan Sen, MD and Aman Verma, DO
    Cleveland Clinic Journal of Medicine October 2023, 90 (10) 603-605; DOI: https://doi.org/10.3949/ccjm.90a.23040

    Research and robust data are still lacking regarding use of midodrine in this setting.